All In Biotech

Drug Trial Radar · NCT07917468

Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer

Sintilimab Combined With Long-Course Concurrent Chemoradiotherapy Followed by Capeox Consolidation Chemotherapy vs. Long-Course Concurrent Chemoradiotherapy Followed by Capeox Consolidation Chemotherapy for Total Neoadjuvant Therapy in Patients With Mismatch Repair-Proficient (pMMR) or Microsatellite Stable/Low Microsatellite Instability (MSS/MSI-L) Locally Advanced Rectal Cancer: A Multicenter, Randomized, Double-Blind, Controlled Phase III Study

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Nov 25, 2026

Primary completion

Mar 25, 2030

Study completion Nov 24, 2031

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, controlled, Phase III clinical study to evaluate the efficacy and safety of sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy, which is planned to enroll 500 subjects with locally advanced rectal cancer.

Conditions

  • Locally Advanced Rectal Cancer

Interventions

  • OxaliplatinDrug

    130 mg/m²,IV,Q3W

  • PlaceboDrug

    20 ml D1 IV Q3W

  • radiotherapyRadiation

    PTV1 50 Gy/25 times, PTV2 45 Gy/25 times, 5 days a week, for a total of 5 weeks (D1-D35)

  • CapecitabineDrug

    825 mg/m ² PO BID ,Days 1-5 QW;1000mg/m ² PO BID ,Days 1-14 Q3W;

  • Radical resection of rectal cancerProcedure

    Radical resection of rectal cancer

  • SintilimabDrug

    200 mg D1 IV Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EFSTime frame: throutg treatment completion an average of 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.